{"id":"iomazenil-123i","rwe":[{"pmid":"35907190","year":"2023","title":"Neuronal dysfunction and hemodynamic disturbance due to venous congestion in dural arteriovenous fistula revealed by 123I-iomazenil SPECT.","finding":"","journal":"Journal of neurosurgery","studyType":"Clinical Study"},{"pmid":"21959128","year":"2012","title":"Decreased benzodiazepine receptor and increased GABA level in cortical tubers in tuberous sclerosis complex.","finding":"","journal":"Brain & development","studyType":"Clinical Study"},{"pmid":"20133106","year":"2010","title":"Epileptic negative myoclonus: a combined study of EEG and [123I]iomazenil (123I-IMZ) single photon emission computed tomography indicating involvement of medial frontal area.","finding":"","journal":"Epilepsy research","studyType":"Clinical Study"},{"pmid":"15987275","year":"2005","title":"Central-type benzodiazepine receptors and epileptogenesis: basic mechanisms and clinical validity.","finding":"","journal":"Epilepsia","studyType":"Clinical Study"},{"pmid":"9038063","year":"1997","title":"[Assessment of cerebral benzodiazepine receptor distribution in epilepsy by 123I-iomazenil-SPECT].","finding":"","journal":"Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica","studyType":"Clinical Study"}],"tags":[{"label":"iomazenil (123I)","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":["NCT00611572","NCT01590277","NCT00982982"],"aliases":[],"patents":[],"pricing":[],"allNames":"iomazenil","offLabel":[],"synonyms":["iomazenil","iomazenil (123I)"],"timeline":[],"approvals":[],"brandName":"Iomazenil","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"iomazenil (123I)","explanation":"Think of it like a key fitting into a lock. Iomazenil (123I) is a small molecule that binds to a specific receptor in the brain, called the benzodiazepine receptor. This binding can help doctors understand how the brain is working and identify potential problems.","oneSentence":"Iomazenil (123I) works by binding to the benzodiazepine receptor in the brain.","technicalDetail":"Iomazenil (123I) is a selective antagonist of the central benzodiazepine receptor, which is a GABA_A receptor subtype. Its binding to this receptor can modulate the activity of GABA, a major inhibitory neurotransmitter in the brain."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Iomazenil","title":"Iomazenil","extract":"Iomazenil is an antagonist and partial inverse agonist of benzodiazepine and a potential treatment for alcohol use disorder. The compound was introduced in 1989 by pharmaceutical company Hoffmann-La Roche as an Iodine-123-labelled SPECT tracer for imaging benzodiazepine receptors in the brain. Iomazenil is an analogue of flumazenil (Ro15-1788)."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1462","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IOMAZENIL (123I)","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://en.wikipedia.org/wiki/Iomazenil","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T12:08:03.494423","biosimilars":[],"competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"iomazenil (123i)","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00611572","phase":"Phase 1","title":"Contribution of Gabaergic and Glutamatergic Mechanisms to Cognitive Dysfunction","status":"COMPLETED","sponsor":"Yale University","isPivotal":false,"enrollment":23,"indication":"Cognitive Dysfunction","completionDate":"2018-10-02"},{"nctId":"NCT01590277","phase":"Phase 1","title":"Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans","status":"COMPLETED","sponsor":"VA Office of Research and Development","isPivotal":false,"enrollment":33,"indication":"Active Ethanol and Active Iomazenil, Active Ethanol and Placebo Iomazenil","completionDate":"2018-11-02"},{"nctId":"NCT00982982","phase":"EARLY/Phase 1","title":"Gamma-Amino Butyric Acid (GABA) Deficits and Vulnerability to Cannabinoid-Induced Psychosis","status":"COMPLETED","sponsor":"Yale University","isPivotal":false,"enrollment":17,"indication":"Schizophrenia, Mental Disorders","completionDate":"2013-02-22"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"7DVX185FLQ","CHEBI":"CHEBI:135665","UMLSCUI":"C1273079","ChEMBL_ID":"CHEMBL2105020","KEGG_DRUG":"D02283","DRUGBANK_ID":"DB14971","PUBCHEM_CID":"65959","SECONDARY_CAS_RN":"127985-21-1","MESH_SUPPLEMENTAL_RECORD_UI":"C063038"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":7,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"recentPublications":[{"date":"2023 Mar 1","pmid":"35907190","title":"Neuronal dysfunction and hemodynamic disturbance due to venous congestion in dural arteriovenous fistula revealed by 123I-iomazenil SPECT.","journal":"Journal of neurosurgery"},{"date":"2012 Jun","pmid":"21959128","title":"Decreased benzodiazepine receptor and increased GABA level in cortical tubers in tuberous sclerosis complex.","journal":"Brain & development"},{"date":"2010 May","pmid":"20133106","title":"Epileptic negative myoclonus: a combined study of EEG and [123I]iomazenil (123I-IMZ) single photon emission computed tomography indicating involvement of medial frontal area.","journal":"Epilepsy research"},{"date":"2005","pmid":"15987275","title":"Central-type benzodiazepine receptors and epileptogenesis: basic mechanisms and clinical validity.","journal":"Epilepsia"},{"date":"1997 Jan","pmid":"9038063","title":"[Assessment of cerebral benzodiazepine receptor distribution in epilepsy by 123I-iomazenil-SPECT].","journal":"Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Iomazenil (123I) is a small molecule radiopharmaceutical drug of the iomazenil class. Its exact target is unknown, but it is used in clinical settings. Iomazenil (123I) is not FDA-approved for any indications, and its commercial status, patent status, and availability of generic manufacturers are also unknown. Further research is needed to understand its pharmacokinetic properties, including half-life and bioavailability. As a result, key safety considerations and clinical applications remain unclear.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}